Advertisement

Topics

Clinical Trials About "Approves Extension Treatment Short Bowel Syndrome Include Children" RSS

04:37 EDT 17th June 2019 | BioPortfolio

We list hundreds of Clinical Trials about "Approves Extension Treatment Short Bowel Syndrome Include Children" on BioPortfolio. We draw our references from global clinical trials data listed on ClinicalTrials.gov and refresh our database daily.

More Information about "Approves Extension Treatment Short Bowel Syndrome Include Children" on BioPortfolio

We have published hundreds of Approves Extension Treatment Short Bowel Syndrome Include Children news stories on BioPortfolio along with dozens of Approves Extension Treatment Short Bowel Syndrome Include Children Clinical Trials and PubMed Articles about Approves Extension Treatment Short Bowel Syndrome Include Children for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Approves Extension Treatment Short Bowel Syndrome Include Children Companies in our database. You can also find out about relevant Approves Extension Treatment Short Bowel Syndrome Include Children Drugs and Medications on this site too.

Showing "Approves Extension Treatment Short Bowel Syndrome Include Children" Clinical Trials 1–25 of 37,000+

Extremely Relevant

An Extension Study of Teduglutide in Japanese Participants With Short Bowel Syndrome Who Completed 24 Weeks of Treatment in SHP633-306 or TED-C14-004

The purpose of this clinical study is to evaluate the long-term safety and efficacy of teduglutide in Japanese participants with PN/IV (parenteral nutrition/intravenous)-dependent SBS (short bowel syndrome) who completed SHP633-306 or who were in the extension phase of the TED-C14-004 (NCT02340819) study.


Evaluation of the Efficacy and Safety of Recombinant Human Growth Hormone (rhGH) in the Treatment of Children With Short Bowel Syndrome

This is a randomized controlled, parallel group, open label versus "no treatment" trial which evaluate the efficacy of rhGH on weaning off parenteral nutrition in children with short bowel syndrome.The total follow-up is 14 months; 4 months for each group after randomization; At the end of the first four months: the treated group will be followed within 6 months, the untreated group will receive compassionately rhGH for 4 months and followed-up for 6 months after the end of the...

A Study in Japanese Children With Short Bowel Syndrome Who Completed SHP633-302

The purpose of this study is to evaluate long-term safety and efficacy of teduglutide treatment in Japanese children with Short Bowel Syndrome (SBS) who have already completed the SHP633-302 study.


Pharmacokinetics of Citalopram in Patients With Short Bowel Syndrome

This prospective study will determine the pharmacokinetic parameters of citalopram in 12 adult patients with short bowel syndrome. While data on the prevalence of depression in patients with short bowel syndrome is sparse, the investigators' experience is that these patients have a high incidence of depression and should benefit from a psychopharmacological intervention.

A Phase III Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Investigational Product MP-101 in Subjects With Short Bowel Syndrome Who Have Had an Inadequate Response to Anti-Diarrheals

MP-101 will be evaluated in this study to see if it is safe, tolerable, and can help people with Short Bowel Syndrome. This study will also find out if taking MP-101 can improve the symptoms of Short Bowel Syndrome and reduce the number of times subjects experience bowel movements.

A Study of Teduglutide in Children With Short Bowel Syndrome Who Are Dependent on IV Fluids or Nutrition

Teduglutide is currently an approved medicine for adults with short bowel syndrome (SBS). This is a study to evaluate the safety and efficacy of teduglutide in children up to the age of 17 with (SBS) who are dependent on parenteral support (IV fluids or IV nutrition). Children who enroll in the treatment group will be randomly assigned to receive one of two doses of teduglutide to be given daily for 24 weeks. Children may alternatively enroll in a standard of care group that do...

Fiber Use in Pediatric Short Bowel Syndrome

Short bowel syndrome (SBS) is a form of disease that results from removal of a significant portion of the intestine leading to poor nutrient absorption. Infants with short bowel syndrome suffer from diarrhea and poor growth. The care of these infants is limited by the lack of effective therapies. Soluble fiber (guar gum) is an indigestible form of sugar that is mostly contained in fruits and vegetables. Soluble fiber can reduce the severity and duration of persistent (constant...

Long-term Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome Who Completed the TED-C13-003 Study

The purpose of this study is to evaluate the safety and efficacy of teduglutide treatment of children with short bowel syndrome (SBS) who completed the TED-C13-003 study over a long-term period. It will evaluate how these children fared after the TED-C13-003 study ended. This study will also offer teduglutide treatment to eligible subjects, regardless of treatment received in TED-C13-003.

Open-Label Study of Teduglutide for Subjects With PN-Dependent Short Bowel Syndrome (SBS)

This study is a 2-year open label extension study to collect long term efficacy and safety data from patients who have completed the 24-weeks of study drug dosing in CL0600-020.

Intestinal Microbial Dysbiosis in Chinese Infants With Short Bowel Syndrome With Different Complications

There are no reports involved the intestinal microbiota from Chinese infants with short bowel syndrome (SBS) under different clinical status. Alterations in the microbiota are closely correlated with the bile acids and short chain fatty acids metabolism as well as the intestinal immunity. A relatively comprehensive profile composed of microbial structure, microbial metabolism products and immune biomarkers in SBS infants may facilitate a better therapy strategy to complications...

Study of Teduglutide in Japanese Participants With Short Bowel Syndrome

The objectives of this clinical study are to evaluate the safety, efficacy, and pharmacokinetics (PK) of teduglutide in Japanese participants with short bowel syndrome (SBS) who are dependent on parenteral nutrition/intravenous (PN/IV) over a 24-week treatment period.

Safety, Efficacy and Pharmacokinetic Study of Teduglutide in Infants 4 to 12 Months of Age With Short Bowel Syndrome

The purpose of the study is to evaluate the safety, efficacy/pharmacodynamics (PD) and pharmacokinetics (PK) of teduglutide treatment in infants with short bowel syndrome (SBS) dependent on parenteral (PN) support.

Safety and Efficacy Study of Teduglutide in Subjects With Short Bowel Syndrome

The purpose of this study is to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of teduglutide compared with placebo in subjects with parenteral nutrition (PN)-dependent short bowel syndrome (SBS).

Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS

The primary objective of the trial is to confirm the efficacy of glepaglutide in reducing parenteral support volume in patients with short bowel syndrome. Glepaglutide is the International Nonproprietary Name and USAN for ZP1848.

Safety, Efficacy, PD of FE203799 in Short Bowel Syndrome on Parenteral Support

once weekly dosing for 4 weeks in patients with short bowel syndrome who require total parenteral nutrition; patients will complete period 1 and after a 6-10 week wash-out, they will enter period 2 (active treatment and placebo)

Amino Acid-based Oral Rehydration Solution in Children With Short Bowel Syndrome

This study will assess the tolerability and palatability of an amino acid based oral rehydration solution (enterade®) compared to current oral rehydration solution among children with short bowel syndrome .

Effect of the Enteric Hormone Glucagon-Like Peptide (GLP-2) on the Intestinal Blood Flow in Patients With Short Bowel Syndrome

The aim of the study is to investigate the effect of the enteric hormone Glucagon-like Peptide (GLP-2) on patients with short bowel syndrome

Relevant

Long-term Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome (SBS) Who Completed TED-C14-006

This study will follow subjects who completed the TED-C14-006 study. The purpose of this study is to evaluate the long-term safety and efficacy of teduglutide in pediatric subjects with Short Bowel Syndrome (SBS). This study will also offer teduglutide treatment to eligible subjects, regardless of treatment received in TED-C14-006.

Immunological Change and the Single Nucleotide Polymorphism (SNP) in Children With Irritable Bowel Syndrome (IBS)

Currently, the pathophysiology of Irritable bowel syndrome( IBS) remains unclear . The purpose of this study is want to investigate the immunological changes in the children with IBS.

Study in Japanese Pediatric Subjects With Short Bowel Syndrome (SBS) Who Are Dependent on Parenteral Support

The purpose of this study is to determine if an investigational treatment (teduglutide) is safe and effective in Japanese children (age 1 through 15 years of age) with SBS who are dependent on parenteral support. This study will also evaluate how teduglutide moves through the body (pharmacokinetics) and how it affects the body (pharmacodynamics).

Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS

The primary objective of the trial is to evaluate the long-term safety of glepaglutide treatment in patients with short bowel syndrome (SBS). Glepaglutide is the International Nonproprietary Name and USAN for ZP1848.

Evaluate the Efficacy and Safety Growth Hormone, Glutamine and Diet in Patients With Short Bowel Syndrome (SBS)

Treatment for 3.5-8 weeks with GH (0.05 mg/kg/day) +GLN+Diet, followed by continued compliance to the individualized oral diet and enteral GLN, will result in reduced volume of TPN infusion/week and/or reduced frequency of TPN infusions/week.

Liraglutide on Decreasing Parenteral Support in Short Bowel Patients (SLIPS)

Pilot study looking at the effect on Liraglutide in the reduction of parenteral support in patients with short bowel.

A Open Label Extension Study for Subjects That Complete Study MP-101-CL-001

MP-101 will be evaluated in this study to see if it is safe and tolerable.

The Use of VSL#3 in Irritable Bowel Syndrome in Children

The goal of this study is to determine whether the oral administration of the probiotic VSL#3 under randomized, placebo-controlled conditions will improve symptoms of irritable bowel syndrome in children, safely.


More From BioPortfolio on "Approves Extension Treatment Short Bowel Syndrome Include Children"

Advertisement
Quick Search
Advertisement
Advertisement